ResearchMoz include new market research report "Competitor Landscape: Sjogrens Syndrome" to its huge collection of research reports.
Competitor Landscape: Sjgren's Syndrome
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Sjgren's Syndrome market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Fill the form for an exclusive sample of this report @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978467
Key Highlights
- Primary completion date of Phase II RSLV-132 trial changed from October 2018 to July 2018 and status changed from active, not recruiting to completed
- Gilead announced that data from the Phase II study in Sjgrens syndrome is anticipated in H1 2019
- GSK announced that proof-of-concept data for its Phase II belimumab + rituximab trial in Sjgrens syndrome is expected in H1 2020.
Scope
- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
Browse Complete Report with TOC @ https://www.researchmoz.us/competitor-landscape-sjogrens-syndrome-report.html/toc
Reasons to buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Pipeline Landscape
Overview: Pipeline Candidates ( Phase II)
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978467
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Blog: https://studyanalyst.blogspot.in
Competitor Landscape: Sjgren's Syndrome
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Sjgren's Syndrome market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Fill the form for an exclusive sample of this report @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978467
Key Highlights
- Primary completion date of Phase II RSLV-132 trial changed from October 2018 to July 2018 and status changed from active, not recruiting to completed
- Gilead announced that data from the Phase II study in Sjgrens syndrome is anticipated in H1 2019
- GSK announced that proof-of-concept data for its Phase II belimumab + rituximab trial in Sjgrens syndrome is expected in H1 2020.
Scope
- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
Browse Complete Report with TOC @ https://www.researchmoz.us/competitor-landscape-sjogrens-syndrome-report.html/toc
Reasons to buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Pipeline Landscape
Overview: Pipeline Candidates ( Phase II)
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978467
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Blog: https://studyanalyst.blogspot.in
Comments
Post a Comment